NEW YORK--(BUSINESS WIRE)--July 11, 2006--ZIOPHARM Oncology, Inc. (OTC BB: ZIOP - News) announced today that Lawrence Boise, Ph.D., University of Miami, a preclinical investigator for the Company's clinical candidate ZIO-101, served as the discussion leader at the 2006 Gordon Research Conference at the University of Oxford in the U.K. The meeting is focused on "Metals in Medicine" and is taking place from July 9-14, 2006. Dr. Boise chaired the session titled "Metals and Apoptosis: Therapeutic Implications" and will discuss his experience with ZIO-101, an organic arsenic, as part of a review on the clinical utility of arsenic compounds. The Gordon Research Conferences provide an international forum for the presentation and discussion of frontier research in the biological, chemical, and physical sciences, and their related technologies.
